Oculis Advances Phase 3 Clinical Trials for OCS-01 in DME

Oculis Holding AG (Oculis) has sped up the enrollment of patients for the phase 3 DIAMOND clinical trials of OCS-01 eye drops in DME and expanded the DIAMOND programme committees with leading retina specialists worldwide.

Significant advancement in enrollment has been made from the end of Q2 2024 to early October, with around 70% of participants enlisted in the phase 3 DIAMOND-1 trial, and approximately 40% in the phase 3 DIAMOND-2 trial. The DIAMOND program, which stands for DIAbetic Macular edema patients ON a Drop, includes two phase 3, double-masked, randomized, multi-center trials to assess the safety and efficacy of OCS-01 eye drops in DME patients.

Arshad M. Khanani, M.D., M.A, FASRS, DIAMOND Programme Steering Committee Chairperson, Oculis Board of Directors member, Scientific Advisory Board Chair of Retina and Director of Clinical Research at Sierra Eye Associates, commented: “I am honoured to chair the DIAMOND steering committee, comprised of leading experts from around the globe, as we support the outstanding team at Oculis in the late-stage development of OCS-01. The results from Stage 1 of the DIAMOND phase 3 programme are promising, showing that patients treated with OCS-01 experienced significant improvements in visual acuity and a clinically meaningful reduction in macular edema. The DIAMOND programme offers hope to the millions worldwide affected by DME, with OCS-01 potentially emerging as the first non-invasive topical eye drop therapy."